Applied Dna Sciences Inc (NASDAQ:APDN) Sentiment Up to 2.67, Despite

“Big money sentiment for Applied Dna Sciences Inc (NASDAQ:APDN) in 2018 Q3 increased to 2.67, SEC filings reveal. That’s up 1.24, from 2018Q2’s …

Applied DNA Sciences, Inc. (NASDAQ:APDN) Corporate Logo

Positions for Applied Dna Sciences Inc (NASDAQ:APDN)

“Big money sentiment for Applied Dna Sciences Inc (NASDAQ:APDN) in 2018 Q3 increased to 2.67, SEC filings reveal. That’s up 1.24, from 2018Q2’s 1.43. 16 hedge funds started new or increased equity positions, while 6 sold and reduced their stock positions in Applied Dna Sciences Inc so the sentiment has improved. Funds own 1.81 million shares, down from 1.96 million shares in 2018Q2. Funds holding Applied Dna Sciences Inc in top 10 changed to 0 from 0 for the same number . 5 Investors Sold All; 1 Reduced Holdings; 8 increased holdings while 8 hedge funds bought holdings.

Largest Applied Dna Sciences Inc Shareholders

As of 2018 Q3 Chase Investment Counsel Corp has 0.1% invested in Applied Dna Sciences Inc. Applied Dna Sciences Inc’s shareholder Benchmark Capital Advisors owns 50,000 shares as of 2018 Q3. Thompson Davis & Co. Inc. reported 6,000 shares. The California-based fund Reilly Financial Advisors Llc have invested about 0.01% of the investment manager’s stock portfolio in Applied Dna Sciences Inc. The North Carolina-based fund Bank Of America Corp De looks positive on Applied Dna Sciences Inc, possessing 6,366 shares.

Applied DNA Sciences, Inc. provides biotechnology based security solutions for supply chain security, brand protection, and law enforcement applications in the United States, Europe, and Asia.The firm is valued at $15.74 million. The company’s supply chain security and product authentication solutions include SigNature DNA markers that are ingredients used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNature T DNA markers, which are tagging and authentication systems for use in brand protection efforts and raw material source compliance programs; and fiberTyping, a test of native cotton fiber.Last it reported negative earnings. It also provides DNAnet, a DNA marker to link evidence and offenders to specific crime scenes; Beacon locked optical markers are encrypted mechanisms, which create a protected covert screening tool that can be adapted to packaging, security labels, and high–value assets through inks, varnishes, and coatings; and SigNify IF portable DNA reader that provides real-time authentication of in the field–DNA.

The stock decreased 0.45% or $0.002 during the last trading session, reaching $0.442.Currently Applied DNA Sciences, Inc. is downtrending after 54.35% change in last January 22, 2018. APDN has also 149,403 shares volume. The stock underperformed the S&P 500 by 54.35%.

Hightower Lc owns 11,067 shs. The New York-based Morgan Stanley has invested 0% in Applied DNA Sciences, Inc. (NASDAQ:APDN). Reilly Limited Liability Corporation accumulated 50,000 shs. Northern Trust invested 0% in Applied DNA Sciences, Inc. (NASDAQ:APDN). Chase Invest Counsel Corporation invested in 131,163 shs or 0.1% of the stock. 107,534 were accumulated by Creative Planning. Cwm Llc reported 0% in Applied DNA Sciences, Inc. (NASDAQ:APDN). Gluskin Sheff And Associates reported 20,000 shs. Mycio Wealth Limited Liability Corporation reported 25,000 shs. California Pub Employees Retirement System has invested 0% in Applied DNA Sciences, Inc. (NASDAQ:APDN). Citigroup has invested 0% in Applied DNA Sciences, Inc. (NASDAQ:APDN). Massachusetts-based Geode Mgmt Lc has invested 0% in Applied DNA Sciences, Inc. (NASDAQ:APDN). Vanguard has invested 0% in Applied DNA Sciences, Inc. (NASDAQ:APDN). Regions Corporation accumulated 9,100 shs or 0% of the stock. 10,000 were reported by Taurus Asset Management Ltd Co.

For more Applied DNA Sciences, Inc. (NASDAQ:APDN) news published briefly go to:,,, or The titles are as follows: “Midday Gainers / Losers – Seeking Alpha” published on December 14, 2018, “Applied DNA and Eurofins BLC Sign Collaboration Agreement to Support Commercial Implementation of Leather Traceability System – Business Wire” on November 19, 2018, “Applied DNA Sciences secures $4.8M private capital raise; shares down 25% – Seeking Alpha” with a publish date: December 20, 2017, “Applied DNA Announces Proposed Public Offering of Common Stock and Warrants – Business Wire” and the last “Premarket Gainers as of 9:05 am (09/25/2018) – Seeking Alpha” with publication date: September 25, 2018.

Applied DNA Sciences, Inc. (NASDAQ:APDN) Analyst Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Gene Expression Analysis Market 2018 Detailed Global Analysis by Emerging Technology with …

The report Gene Expression Analysis Market by Key players highlights the essential market dynamics of Gene Expression Analysis sector.
Gene Expression Analysis Market

Gene Expression Analysis Market

The report Gene Expression Analysis Market by Key players highlights the essential market dynamics of Gene Expression Analysis sector. The efficiency of this segment has been studied deeply along with the noteworthy challenges and forthcoming growth opportunities and prospective. The report focuses in decision making abilities and supports to make effective counter strategies in order to achieve competitive advantage. Current market scenario of the segment and forecasts of the market situation have also been bounded in this market report.

The report gives the clear picture of current Gene Expression Analysis Market scenario and the predicted future of the industry. The report focuses on the basis of market drivers, restraints, growth, trends and forecast for the period of 2018-2024. In addition, the report also maps the market performance by value chain analysis which will help in better product differentiation along with the analysis of each segment in terms of opportunity, market attractiveness index and growth rate.

Get Sample Copy of This Report @…

Global Gene Expression Analysis Market Players –

• General Electric

• Danaher

• Thermo Fisher Scientific Inc.

• F. Hoffmann-La Roche Ltd

• Illumina, Inc.


• Merck & Co., Inc.

• Agilent Technologies

• Bio-Rad Laboratories, Inc.

• Genotypic Technology Pvt Ltd

• QIAGEN, Macrogen, Inc.

• Eurofins Scientific

• PerkinElmer Inc.

• Personalis Inc.

• Novogene Corporation

• SciGenom Labs Pvt. Ltd


• Kohlberg Kravis Roberts & Co. L.P.


• Agilent Technologies

• Genomatix GmbH

• Pacific Biosciences of California, Inc.

• Biomatters Limited

• Strand Life Sciences Pvt. Ltd


• New England Biolabs

• Among others.

Market Analysis: Global Gene Expression Analysis Market

The Global Gene Expression Analysis Market accounted to USD 3.50 billion in 2016 growing at a CAGR of 9.5% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

The gene expression is the method used for extracting data from a gene which will be used for the production of a practical gene product. With the help of gene expression, the genetic code reserved in DNA can be calculated. The research can be used for the classification of the diseases, which led its wide range of applications such as pharmacogenomics, diagnostics, biomarkers, and toxicology.

BUY NOW With Best Discounts @…

By consumables:

• Reagents

• DNA Chips

On the basis of technology:

• Polymerase Chain Reaction

• Next-Generation Sequencing

• Dna Microarray

• Serial Analysis Of Gene Expression

• Northern Blotting

On the basis of application:

• Research

• Drug Discovery

• Diagnostics

On the basis of services:

• Gene Expression Profiling Services

• Sequencing Services

• Bioinformatics Solutions

• Others

On the basis of end-user:

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

• Contract Research Organizations

• Other End Users

On the basis of geography:

• North America

• South America

• Europe

• Asia-Pacific

• Middle East & Africa

Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.


1. The analysis of Gene Expression Analysis Market, their Growth, Demand, position, size and share from different regions are mentioned in detailed.

2. The key players in the market and their share in the global market are discussed.

3. The new strategic plan and suggestions that will help old as well as new market players to maintain the competitiveness are also discussed.

4. The Gene Expression Analysis Market report provides some important points related to growth factors, challenges, opportunities, end-user analysis and achievement and so on.

Access Detailed TOC @…

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

Tel: +1-888-387-2818


This release was published on openPR.

Related Posts:

  • No Related Posts

Protein Expression Market: By Current Industry Status,Growth Opportunities, Top Key Players …

… Lonza Group Ltd., New England Biolabs Inc., Sengenics, Proteogenix, Synthetic Genomics Inc. By Product Type: s & ServicesReagents, Expression …

Protein Expression Market in

Protein Expression Market Report analyse current as well as future aspects of the Protein Expression Industry. The Protein Expression Market provides Protein Expression demand, trends and segmentation analysis. Global Protein Expression industry Report presents the up to date and useful market insights stating the product definition, product type, variety of applications.

About Protein Expression:

The Research projects that the Protein Expression market size will grow from in 2017 to by 2023, at an estimated CAGR of XX%. The base year considered for the study is 2017, and the market size is projected from 2018 to 2023.Protein expression is a technique or methodology in which proteins are characterized, modified, and synthesized in the host cells. The selected protein is typically achieved by the modification or alteration of the protein expression process in a living cell. Various kinds of protein expression systems are used for the production of a broad range of therapeutic proteins such as insulin, interferons, and interleukins.

Get Sample and Full TOC of the Report


Report Coverage:

  • WorldwideMarket Size of Protein Expression 2012-2017, and development forecast 2018-2023.
  • Main Manufacturers/suppliers of Protein Expression worldwide and market share by regions, with company and product introduction, position in the Protein Expression market.
  • Market status and development trend of Protein Expression by types and applications.
  • Cost and profit status of Protein Expression Market, and marketing status.
  • Market growth drivers and challenges.

Protein Expression Market With Key Segments:

  • By Key Players: Thermo Fisher Scientific Inc., Merck KGaA, Genscript Biotech Corporation, Agilent Technologies, Inc., Takara Bio Inc., Promega Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., Lonza Group Ltd., New England Biolabs Inc., Sengenics, Proteogenix, Synthetic Genomics Inc.
  • By Product Type: s & ServicesReagents, Expression Vectors, Competent Cells, Instruments, Services
  • By Application: Therapeutic Applications, Industrial Application, Research Applications

Global Protein Expression Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

  • North America (United States, Canada and Mexico)
  • Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
  • Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Target Audience of Protein Expression Market:

  • Manufacturer / Potential Investors
  • Traders, Distributors, Wholesalers, Retailers, Importers and Exporters.
  • Association and government bodies.

Have any special requirement on above Protein Expression market report? Ask to our Industry Expert


Key questions answered in theProtein Expression Marketreport:

  • What will the Protein Expression Market Size and the Growth rate be in 2023?
  • What are the key market trends impacting the growth of the Protein Expression market?
  • Who are the global key manufacturers of Protein Expression industry: Company Introduction, Product Specification and Major Types Analysis, Production Market Performance, Sales Market Performance, Contact Information.
  • What are the types and applications of Protein Expression? What is the market share of each type and application: production, revenue, price, Market Size (Sales) Market Share by Type.
  • What are the upstream raw materials and manufacturing equipment of Protein Expression Market? Up Stream Industries Analysis, Raw Material and Suppliers, Equipment and Suppliers, Manufacturing Analysis, Manufacturing Process, Manufacturing Cost Structure, Manufacturing Plants Distribution Analysis, Industry Chain Structure Analysis
  • What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Protein Expression?
  • What are the Protein Expression market opportunities and threats faced by the vendors in the global Protein Expression Industry?

Purchase Complete Protein Expression Market Report at



Related Posts:

  • No Related Posts

Digital therapeutics company Kaia Health raises US$10m in Series A funding

Back pain app creator, Kaia Health, today announces it has raised US$10 million in a Series A round led by Balderton Capital. The investment will be …
Kaia Health team

Back pain app creator, Kaia Health, today announces it has raised US$10 million in a Series A round led by Balderton Capital. The investment will be used to support Kaia Health’s US rollout, including a new office in New York City, and fund further clinical studies.

Since launching in 2016, Kaia Health has created digital treatments for a range of disorders including back pain. Its Kaia back pain app has been adopted by over 250,000 individuals as well as organisations across Europe and the USA. This includes some of Europe’s biggest health insurance companies, such as BARMER, Germany’s largest, which offers the service free to members.

Kaia Health develops machine learning and computer vision technology and works with medical experts to create a home-based, affordable and clinically-validated alternative to painkillers, delivered through a smartphone. The app offers users a daily plan which features physical exercises, relaxation techniques and medical educational content.

Additionally, therapy can be tailored for each user via a proprietary algorithm which adapts the exercise program to that individual’s input. Patent-pending motion tracking technology monitors and provides real-time audio feedback on patients’ exercise performance. Uniquely, Kaia’s app informs users in natural language if they’re performing exercises correctly, and how to improve them—without requiring any extra hardware.

‘Epidemic levels’

With back pain being one of the leading self-reported medical issues in the world, proven digital alternatives to painkillers cannot come soon enough. In America alone the condition is estimated to affect 100 million people a year and is the number one reason why people are prescribed painkillers. The growing use of opioid-based painkillers has driven reliance on such drugs in the USA to epidemic levels.

Meanwhile, in the UK, 30% of all GP appointments are musculoskeletal-related, costing the NHS at least £5bn a year. Reducing the need to prescribe painkillers and the number of MSK interventions is not just a beneficial outcome for patients, but it will also release resources for healthcare institutions to use elsewhere.

Kaia Health is a member of the Digital Therapeutics Alliance, an association of international manufacturers for digital therapeutic products which works to expand access to high quality, evidence-based digital therapeutics to improve outcomes.

(Visited 46 times, 18 visits today)

Related Posts:

  • No Related Posts

Metabolon Appoints Michael Rasche as President of International Business

RALEIGH, N.C. & POTSDAM, Germany–(BUSINESS WIRE)–Metabolon, the world leader in metabolomics, today announced that Michael Rasche …

RALEIGH, N.C. & POTSDAM, Germany–(BUSINESS WIRE)–Metabolon, the world leader in metabolomics, today announced that Michael Rasche joined the company as President of International Business. Michael will report to Rohan Hastie, Metabolon’s President and CEO, and become a member of the corporate executive team. He will lead all of Metabolon’s international business activities with a strong focus on customer and team expansion.

“We are thrilled to have Michael join the Metabolon team,” said Hastie. “Michael brings a wealth of commercial and business experience across multiple areas of life sciences, from Pharma to Diagnostics and Biotech. I know he will make an immediate impact on our existing and future customers.”

“I am very excited to become part of the Metabolon success story,” added Rasche. “I will passionately lead our team to drive accelerated business expansion across all international markets. Our Precision Metabolomics™ technology is delivering biomarker discoveries, innovative diagnostic tests, and groundbreaking data in genomics and population health initiatives. The breadth of possible applications positions us uniquely in life science research.”

Rasche’s track record in international business expansion in Pharma, Diagnostics, and Biotech will contribute to advancing Metabolon’s position as the world leader in metabolomics. He brings 28 years of experience in the healthcare and life science arena, with a particular focus on the interface between Pharma and Diagnostics. Rasche joins Metabolon from Definiens where he was Chief Commercial Officer. Prior to Definiens, Rasche was Corporate Vice President of Global Commercial Operations at Ayoxxa. He has also held leadership positions with Dako (today Agilent), Roche and Bayer Diagnostics both in Europe and the Americas across nine different countries.

About Metabolon

Metabolon is the world’s leading health technology company advancing metabolomics for precision medicine and every area of life sciences research. Metabolon’s Precision Metabolomics™ is a powerful technology for assessing health and is delivering biomarker discoveries, innovative diagnostic tests, and ground-breaking data in genomics and population health initiatives.

Almost every factor impacting the phenotype — from genetics and the microbiome to disease and lifestyle — exerts its influence by altering metabolite levels. By producing the most accurate, comprehensive picture of the metabolome, Metabolon helps answer some of biology’s most challenging questions.

Related Posts:

  • No Related Posts